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short form (SWN-K): reliability and validity in an
Estonian speaking sample
Liina Haring1,2*, René Mõttus3,4, Peeter Jaanson5, Raine Pilli6, Kairi Mägi7 and Eduard Maron8,1Abstract
Background: The Subjective Well-Being Under Neuroleptic Treatment Scale short form (SWN-K) is a self-rating scale
developed to measure mentally ill patients' well-being under the antipsychotic drug treatment. This paper reports
on adaptation and psychometric properties of the instrument in an Estonian psychiatric sample.
Methods: In a naturalistic study design, 124 inpatients or outpatients suffering from the first psychotic episode or
chronic psychotic illness completed the translated SWN-K instrument. Item content analysis, internal consistency
analysis, exploratory principal components analysis, and confirmatory factor analysis were used to construct the
Estonian version of the SWN-K (SWN-K-E). Additionally, socio-demographic and clinical data, observer-rated
psychopathology, medication side effects, daily antipsychotic drug dosages, and general functioning were assessed
at two time points, at baseline and after a 29-week period; the associations of the SWN-K-E scores with these
variables were explored.
Results: After having selected 20 items for the Estonian adaptation, the internal consistency of the total SWN-K-E was
0.93 and the subscale consistencies ranged from 0.70 to 0.80. Good test–retest reliabilities were observed for the
adapted scale scores, with the correlation of the total score over about 6 months being r = 0.70. Confirmatory factor
analysis replicated the presence of a higher-order factor (general well-being) and five first-order factors (mental
functioning, physical functioning, social integration, emotional regulation, and self-control); the model fitted the data
well. The results indicated a moderate-high correlations r = 0.54 between the SWN-K-E total score and the evaluation
how satisfied patients were with their lives in generally. No significant correlations were found between the overall
subjective well-being score and age, severity of the psychopathology, drug adverse effects, or prescribed drug dosage.
Conclusion: Taken together, the results demonstrated that the Estonian version of the SWN-K is a reliable and valid
instrument with psychometric properties similar to the original English version. The potential uses of the scale in both
research and clinical settings are considered.
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There are substantial individual differences in the manifest-
ation, course, and prognosis among patients diagnosed with
a persisting psychotic disorder. In order to reflect such vari-
ability among people with psychotic disorders, psychiatrists
have broadened the concept of treatment outcome beyond* Correspondence: Liina.Haring@kliinikum.ee
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reproduction in any medium, provided the ormere symptom improvement by also addressing related
phenomena such as subjective well-being or quality of life
more generally, management of side effects, subjective
response and tolerability to antipsychotics drugs [1]. The
present study focuses on the subjective well-being of
patients suffering from the psychotic disorder.
The concept of quality of life among the psychiatric
patients has an objective and a subjective component.
The objective component comprises aspects of “func-
tional status” and “environmental living conditions”,
whereas the subjective component refers to perceivedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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both illness and treatment can cause distress and con-
tribute to low well-being evaluations. Patients recognize
the symptoms of their illness and treatment side effects
in similar terms: both can reduce of their well-being.
Furthermore, treatment is perceived negatively not only
if it fails to sufficiently reduce psychotic symptoms and/
or causes substantial side effects but also when it fails to
improve well-being for any reason that is not strictly
related to the disorder or treatment [3].
General subjective well-being is a broad construct that
reflects people's emotional and cognitive evaluations of
their lives [4]. The construct is not specific to psychiatric
patients: it is a robust dimension of individual and popula-
tion differences that can be reliably assessed. Just as among
psychiatric patients, levels of global well-being vary across
healthy individuals [4], cultures [5], and over time [6].
Reported determinants of the self-perceived quality of
life or well-being in persons with persisting psychotic
disorder include socio-demographic characteristics [7,8],
illness-related or clinical characteristics [9,10], psycho-
social characteristics [11], and antipsychotic-related side
effects [10,12,13]. Additionally, weight gain is prevalent
among the patients with schizophrenia and it is asso-
ciated with poorer quality of life ratings [14].
Nevertheless, there remain some issues pertaining to
the assessment of well-being, particularly when the as-
sessments involve different cultures, linguistic groups or
psychiatric patient subgroups. According to the previous
studies, concerns exist over the psychometric properties
of the well-being measures in schizophrenia patients.
The first issue is whether to use objective or subjective
evaluations. Controversy exists over the reliability of
psychotic patients' evaluations of their subjective state.
However, objective assessments made by clinicians
which have correlated poorly with patients' subjective
evaluations of their life quality, are also believed to be
inaccurate reflections of patients' well-being [15-17]. For
example, studies have found that psychiatrists ignore or
tend to minimize patients' complaints about the negative
subjective effects of antipsychotic drugs [18] and ex-
pectations of antipsychotic treatment differ between
patients and physicians [19]. Secondly, the measurement
has to be appropriate to the population under study, the
clinical condition, and the phase of illness; the instru-
ment has to be adapted to the life of psychotic patients
[20] and conform to the context of the culture and value
systems in which the patients live [21].
The “Subjective Well-being Under Neuroleptic Treat-
ment” (SWN) scale was created to evaluate the clinical
relevance of subjective well-being as a subjective meas-
ure of illness and treatment experiences and overall life
satisfaction among psychotic disorder patients who vary
in illness stage and treatments [12,22,23].The present study reports the adaptation of the SWN
into Estonian. Translation and linguistic validation
procedures of the measurements are prerequisite of its
use in a new cultural context and only after standardized
validation it is possible to compare the research data in
a cross-cultural and cross-nation context. The four
major aims of the study are as follows: firstly, the study
seeks to ensure that the Estonian version of the Subject-
ive Well-Being Under Neuroleptic Treatment Scale short
form (SWN-K-E) has the kinds of measurement proper-
ties needed to obtain reliable and valid results; secondly,
to evaluate the usability of the SWN-K on the patients
with the first psychotic episode and on the patients with
chronic psychotic disorder. The underlying assumption
was that the measurement properties of the subjective
well-being scale would be similar for both groups;
thirdly, the aim is to evaluate its measurement stability
over time and its sensitivity in differentiating between
typical or atypical antipsychotic usage. According to the
existing literature, we expected that the SWN-K-E scale
scores are relatively stable over a period of 6 months,
whereas they are to some extent affected by the
psychopharmacotherapy (taking into account drug
dosage and used first or second generation of anti-
psychotics). Fourthly, the study assesses the relationship
of the Estonian SWN-K-E scores with patients' socio-
demographic characteristics, body mass index (BMI),
psychopathology, global functioning, and drug adverse
effects. These associations (or lack of them) provide
information about the validity of the questionnaire but
they also address substantive research questions per-
taining to the correlates of well-being of psychotic
disorder patients. Our expectations were that patients'
subjective well-being perceptions would not significantly
correlate with psychopathology or drugs side effects.
Finally, we assumed that there would be positive
correlation between subjective well-being and general
functioning because both concepts represent outcomes
of the interactions between the patient and the illness,
its treatment, as well as social interaction impacts.
Methods
Sample characteristics
The combined sample consisted of 124 Estonian-speaking
persons, including 68 males (55%) and 56 females (45%)
between the ages of 18 and 78 (M = 35.7, SD = 13.4 years).
A total of 113 participants recompleted the instruments
after period of 24 to 56 weeks (M = 29.70; SD = 7.66)
(response rate 113/124, 91.1%).
The participants with severe physical illness, neuro-
logical disorder or learning disability as well as those with
acute psychotic symptoms or evidence of organic path-
ology were excluded. Psychiatric diagnoses were con-
firmed by examination of medical records to determine
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the 61 outpatients, 55 met ICD-10 (WHO, 1993) criteria for
schizophrenia (F20.08-F29), whereas 6 had schizoaffective
disorders (F25); the 63 inpatients were in the early
stabilization phase of the first psychotic episode (F23 or
F20.09) while they were recruited. The mean age at first
hospitalization was 25.6 years (SD = 7.51) for men and
26.07 (SD = 6.94) years for women. The average illness dur-
ation for the chronic patients (n = 61; 51.6%) was 20.54
(SD = 12.98) years; 63 patients (48.4%) had suffered a first
frank psychotic episode and had received antipsychotic
treatment for a mean of 3.29 (SD = 2.21) weeks. Patients
were treated with various antipsychotic medications as clin-
ically indicated. 99.14% of the patients were receiving anti-
psychotic medications of either atypical (n = 94; 75.80%),
typical (n = 18; 14.51%) or mixed manner (n = 11; 8.87%)
and mean theoretical chlorpromazine dose equivalent [24]
was 515.08 (SD = 335.03) at the recruitment period, and
443.14 (SD = 299.83) at the follow-up assessment. Eighty
eight patients (71%) were treated with only antipsychotics,
10 patients (8%) additionally needed mood stabilizers, 14
(11.3%) and 10 (8.1%) patients respectively received anti-
depressants or hypnotics in addition to antipsychotic
drugs, and 2 patients (1.6%) were on combinations of the
afore-mentioned drugs. All participants were in a stable
phase when they were recruited; self-evaluated scales
addressed the last 7 days. The socio-demographic and
clinical characteristics of the participants are presented
in Table 1.Table 1 Socio-demographic characteristics and clinical profile
Variables Frequencies, mea
(Initial sam
First-episode psychosis
patients
(n = 63)
Socio-demographic data
1. Age 27.03 (6.74)
2. Sex
Males 34 (54.0%)
Females 29 (46.0%)
Clinical profile
1. Treatment duration 23.06 (15.45) days
2. BPRSa 23.70 (13.00)
3. GAFb 52.78 (11.72)
4. BARSc 0.81 (1.79)
5. SASc 0.08 (0.28)
6. AIMSc 0.22 (1.31)
7. Chlorpromazine equivalent dosage 387.54 (155.51)
8. Body mass index 23.91 (3.83)
aMeasure of the severity of psychopathology. bGlobal index of functioning. cDrug aInstruments
Subjective well-being scale
The subjective well-being under the neuroleptic treat-
ment scale (SWN-K) [23] assesses patients' perception
of their health status, antipsychotic treatment, and
nonmedical aspects of their lives. The original version of
the SWN is a 38-item scale initially constructed by
Naber and coworkers [12] and modified by Naber et al.
[23]. This questionnaire is filled out by patients based on
their self-perceived symptoms and level of functioning
during the preceding 7 days. The SWN short form
(SWN-K) consists of 20 statements (10 positive and 10
negative). The SWN has five subscores (mental function-
ing, self-control, emotional regulation, physical function-
ing, and social integration), each consisting of four
questions. The original SWN and SWN-K (short form)
have shown sufficient internal consistency (Cronbach's α
was 0.92 for the total score and 0.63 to 0.82 for the
subscores, whereas the correlation of the short form
total score with the long version was 0.98) [23,25]. It has
been reported that the SWN scores are moderately
correlated with symptomatology evaluations and its
improvement is slightly related to improvement of
psychopathology (r = −0.20 to −0.37). Therefore, the
SWN scale is related to but does not exclusively
evaluate symptomatology, i.e., subjective well-being
cannot strongly be predicted by means of measuring
symptoms of psychotic illness and it is therefore not
redundant [23].of the sample (n = 124)
ns and SD Frequencies, means and SD
ple) (Follow up sample)
Chronically ill
patients
First-episode
psychosis patients
Chronically ill
patients
(n = 61) (n = 58) (n = 55)
44.80 (12.70)
34 (55.7%) 30 (51.7%) 30 (54.5%)
27 (44.3%) 28 (48.3%) 25 (45.5%)
20.5 (12.98) years
19.05 (8.31) 19.05 (11.00) 16.48 (9.19)
50.38 (12.20) 59.57 (13.38) 51.93 (12.46)
1.36 (2.13) 0.55 (1.52) 2.11 (2.53)
0.25 (0.33) 0.08 (0.22) 0.46 (0.50)
2.59 (5.02) 0.15 (0.77) 3.32 (5.92)
646.81 (412.78) 315.28 (140.04) 568.73 (357.97)
26.07 (4.75)
dverse effect scales.
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To adapt the SWN short form into Estonian, we
followed the Principles of Good Practice for the Transla-
tion and Cultural Adaptation Process [26]. The following
translation methodology was used: we received permis-
sion from the authors who developed the SWN and the
SWN short form. Subsequently, two researchers (LH,
KK) independently translated the English version of the
SWN short form 20-item scale into the target language
(Estonian) and three forward-translated versions were
generated for the each statement. Divergent results were
discussed during consensus meetings with a third re-
searcher (HP). After a linguistic translation, no original
item was ruled out as being completely inappropriate for
the subsequent cultural adaptation process. The pre-
final scale version consisted of sixty (three translations
of 20 original items) randomly reordered items. One
independent back-translation was performed by the
professional translator who was blinded to the original
instrument. Items were evaluated by the patients on a
Likert-type scale ranging from 1 (strongly disagree) to 6
(strongly agree). The entire instrument is provided in
Additional file 1.
Satisfaction with life
In addition, participants evaluated an individual item ‘I
am generally satisfied with my life’. The responses were
given using a five-point Likert-scale, ranging from 1
(strongly disagree) to 5 (strongly agree).
Psychopathology
To assess the overall level of psychopathology among
the patients, the clinical scale Brief Psychiatric Rating
Scale (BPRS) [27] was implemented. The BPRS is a
clinician-implemented comprehensive 18-item symptom
scale. Each item is measured along a seven-point con-
tinuum from “not present” to “extremely severe”.
Global functioning
The Global Assessment of Functioning (GAF) is a stand-
ard method for measuring patient's overall level of
functioning and the severity of psychiatric illness. GAF
scores are based on the 100-point scale with descriptions
provided for each 10-point interval (higher scores
indicate better functioning) [28]. Ratings were based on
the clinician's estimate of the patient's current level of
functioning in past 7 days.
Treatment adverse effects
The Barnes Akathisia Rating Scale (BARS) [29] was used
to evaluate drug-induced akathisia. The measurement
uses a 5-point scale ranging from 0 to 4. To assess drug-
induced abnormal movements, the Abnormal Involun-
tary Movement Scale (AIMS) [30] was used. The scalecontains relevant items, rated on a severity scale of 0 to
4 and patient's awareness of abnormal movements, also
rated on a scale of 0 to 4. To assess parkinsonian and
related extrapyramidal side effects, the Simpson-Angus
Scale (SAS) [31] was implemented. This scale contains
10 items; each item is rated on a Likert scale from 0 to
4. A total score is obtained by averaging item scores.
Data collection
The research protocol was approved by the Ethic Review
Committee on Human Research of the University of
Tartu. All participants signed the informed consent after
the nature of the procedures had been fully explained.
Chart audits were done to collect demographic and clin-
ical data. Patients were enrolled between January 2009
and December 2012. The patients were recruited from
Psychiatry Clinic of Tartu University Hospital (n = 61);
from Tartu, Pärnu and Tallinn Psychiatric Outpatients
Centres (n = 33) and institutionalized persons from a
state nursing home (n = 30). The participants were
asked to fill a battery of questionnaires and provide
standard demographic information about their age, gen-
der, and body mass index. Assessments were carried out
at baseline and at 24 to 56 weeks (M = 29.70; SD = 7.66)
after the first examination.
Data analysis
Statistical analyses were conducted using the R Sta-
tistical software package [32]. Analyses focused on the
internal consistency (Cronbach's α) of the SWN-K-E
scales, their dimensionality, and construct validity. The
principal component analysis (PCA) was conducted in
order to replicate the factor structure of the SWN-K-E
inventory. An oblique rotation was used to interpret the
components because the principal components were
inevitably correlated as indicated by the strong first
component [33]. In order to achieve the number of
items and the structure similar to the original scale, we
stepwise-omitted items based on their factor loadings on
their perspective factors (items with weakest loadings
were dropped). Selected items correlated most strongly
with the other items of the subscale and least strongly
with other subscales. The number of factors to extract was
determined using the eigenvalue greater than 1 criterion
(as did the original version of the instrument) and by
examining the screeplot. Items with factor loadings ≥0.40
were retained in the scales.
Congruence between the theoretical structures of the
SWN-K-E with the structure in the collected data was
tested using hierarchical confirmatory factor analysis
(CFA) [34]. In the CFA model, each SWN-K-E item
(treated as ordered-categorical variable as appropriate)
defined its intended factor; no cross-loadings or item
residual correlations were allowed. Then, all latent
Table 2 Psychometric properties of the SWN-K-E (n = 119)
Mean (SD) Cronbach's α Average inter-item
correlation
Total score 84.53 (17.0) [84.79] 0.93 [0.92] 0.37
Mental
functioning
16.44 (4.38) [16.24] 0.77 [0.80] 0.49
Social
integration
16.55 (4.26) [16.44] 0.80 [0.74] 0.50
Emotional
regulation
18.12 (3.92) [17.94] 0.78 [0.73] 0.47
Physical
functioning
16.71 (4.04) [16.90] 0.80 [0.82] 0.50
Self control 16.79 (3.81) [17.28] 0.70 [0.63] 0.37
The analogous scores for the original scale [23] are given in brackets.
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tor. The model was tested using the “lavaan” package [35]
and fitted with Diagonally Weighted Least Squares estima-
tor [36]. Model fit indices such as chi-square fit test, the
root mean square error of approximation (RMSEA) and
the comparative fit index (CFI) were used to evaluate the
degree to which the models fitted data. RMSEA values
lower than 0.06 and CFI values above 0.95 were consid-
ered as evidence for good model fit [37]. Linear multiple
regression was used to test associations between SWN-
K-E scales and continuous variables, whereas t test was
employed to examine any group differences in SWN-K-E.
Associations with p values of less than 0.05 were consi-
dered statistically significant. Less than 0.03% of the data
were missing; therefore, no imputations were made and
pair-wise deletion of missing cases was used where neces-
sary. Evaluated item scores on the SWN-K-E were found
to be sufficiently normally distributed.
Results
Preliminary analysis
Preliminary, analyses were run to achieve the final 20-
item version of the SWN-K-E scale. First, a principal
component analysis was conducted on the data obtained
on the first assessment. The results indicated that all
items loaded on the first unrotated principal component
with loadings ranging from 0.27 to 0.74; the first compo-
nent explained 40.07% of variance in items. According
to the PCA, the principal component intercorrelations
ranged from r = 0.24 to 0.36. Additionally, high
communalities (0.56 to 0.81) indicated that the items
shared substantial amounts of variance with other items.
This suggested there being an overarching well-being
dimension. In the next step, five-factor solution was
considered, based on the intended structure of the
questionnaire.
Internal consistency
The internal consistency of the total SWN-K-E was 0.93,
indicating that selected items showed a reasonable level
of shared variance (Table 2). Internal consistencies of
the subscales ranged from 0.70 to 0.80, again demon-
strating reasonable amounts of shared variance. Item-
total correlations ranged from 0.36 to 0.70.
Construct validity
CFA was conducted with the selected items of the
SWN-K-E in order to replicate the factor structure of
the original SWN-K and obtain parameter estimates for
a hierarchical solution. The loadings of items on their
respective first-order factors varied between 0.56 and
0.83, whereas the loadings of the first-order factors on
the general well-being factor ranged from 0.78 to 0.95,
respectively (Figure 1).The specified model fitted the data well (for fit indices,
see Table 3).
Test and retest reliability
The adapted instrument was administered twice for the
test-retest purposes. Similarly, to the first assessment,
the Cronbach's alpha for all items was 0.93 in the
retesting, respectively. The data of test-retest reliability
can be used to address the issue of instrument stability.
Pearson correlation coefficients were established to
assess the strength of agreement between the scores at
two different times. Subscale correlations between two
testing ranged from 0.55 to 0.68 (for ER r = 0.63, MF
r = 0.65, PF r = 0.57, SC r = 0.55, SI r = 0.68, respectively);
for total scores, the correlation was 0.70. Therefore, in
addition to considerable internal consistency, the SWN-
K-E short form showed reasonable temporal stability.
The mean of the total score at the first assessing was
84.53 (SD = 17.00), which did not differ significantly from
the second-time mean score (83.34; SD = 17.22; df = 103;
t = 1.00; p = ns). Furthermore, the same tendency was seen
among four subscales: MF (M = 16.44 vs. 15.90; SD = 4.38
vs. 4.11; df = 111; t = 1.49; p = ns); PF (M = 16.71 vs. 16.40;
SD = 4.04 vs. 4.02; df = 109; t = 0.18; p = ns); SC (M =
16.79 vs. 16.99; SD = 3.81 vs. 3.65; df = 109; t = −0.59;
p = ns); SI (M = 16.55 vs. 16.63; SD = 4.26 vs. 4.04;
df = 107; t = −0.24; p = ns). However, for the ER subscore a
significant difference occurred (M = 18.12 vs. 17.44; SD =
3.92 vs. 4.27; df = 110; t = 2.13; p = 0.04); this may have
been due to chance, given the number of tests performed.
A CFA model identical to that described above was
fitted to the data from the second measurement and
similar estimates were obtained, suggesting that the
structural model was also replicable (see Table 3).
Association of the subjective well-being scores and
satisfaction with life
The five SWN-K-E facet scales (MF, PF, SC, SI, and ER)
and the total score had moderate to high correlation in
0.56
0.64
0.65
0.67
0.69
0.7
0.7
0.71
0.71
0.72
0.74
0.75
0.76
0.76
0.76
0.77
0.78
0.79
0.8
0.8
0.82
0.83
0.85
0.86
0.95
ER.1
ER.2
ER.3
ER.4
MF.1
MF.2
MF.3
MF.4
PF.1
PF.2
PF.3
PF.4
SC.1
SC.2
SC.3
SC.4
SI.1
SI.2
SI.3
SI.4
ER
MF
PF
SC
SI
GWB
Figure 1 Parameter estimates for the SWN-K-E scale, according to initial testing (n = 120). GWB, subjective well-being total score;
ER, emotional regulation; MF, mental functioning; PF, physical functioning; SC, self-control; SI, social integration; ER.1-SI.4, subscale items, respectively.
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with their lives in general. Significant correlations ranged
from 0.37 to 0.51 for the facets, whereas the correlation
was 0.54 for the SWN-K-E total score.
Subjective well-being index among the first episode
vs. chronic psychotic patients
Different patient groups were compared to assess the
illness-related factors on the SWN-K-E scores. TheTable 3 Goodness-of-fit indicators for the SWN-K-E
hierarchical factor analysis model (n = 120; n = 110)
Chi square df p CFI RMSEA CI
Test 116.156 165 0.999 1.000 0.000 0.000 to 0.000
Retest 129.942 165 0.980 1.000 0.000 0.000 to 0.000
CFI comparative fit index, RMSEA root mean square error of approximation,
CI 90%, confidence interval for RMSEA.comparison was made between patients with first-
episode psychosis and patients with chronic psychotic
disorder. No significant difference appeared between
those two groups in the SWN-K-E total scores (M = 86.86
(SD = 16.10) vs. 82.23 (SD = 17.73); df = 117; t = 1.49;
p = ns), and the same trend was seen among the facets.
The results indicate that the short- or long-term illness or
treatment duration do not make a significant contribution
to the subjective well-being total score.Associations of the SWN-K-E scores with other variables
Correlations between the SWN-K-E total score and the
demographic characteristics
Results showed no differences between men and women
on the SWN-K-E scale total scores: M =83.56 vs. 85.62;
df = 117; t = −0.66; p = ns and the correlation between the
age and SWN-K-E score was non-significant (r = −0.06).
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No significant correlations were found between BMI and
the SWB total index (r = −0.12; p = ns) but inspection of
the SWN-K-E physical functioning subscore and BMI
revealed a modest negative correlation (r = −0.20; p = 0.02).
Associations of the SWN-K-E score and antipsychotic
treatment
Patients with chronic disease were significantly more
often treated with higher antipsychotic drug dosages
compared with first-episode psychosis patients. The
antipsychotic equivalent dosages were calculated [24]
for those two groups at baseline: M = 646.81 vs. 387.54;
df = 122; t = 4.66; p < 0.01, and during the retesting: M =
568.73 vs. 287.94; df = 112; t = 5.48; p < 0.01, respectively.
No significant correlations were found between SWN-K-E
total scores and using antipsychotics dosage at the base-
line (r = −0.14), and during the retesting (r = −0.04). Fur-
thermore, no significant differences occurred between the
SWN-K-E total score and using atypical antipsychotics
(n = 91) versus typical or combination treatment (n = 28)
(M = 84.98 vs. 83.07; df = 117; t = 0.51; p = ns, at the
baseline, and during the retesting: M = 84.58 vs. 81.08;
df = 101; t = 0.90; p = ns, respectively).
Disorder-related dimensions
The patients were characterized by an improvement in
general functioning (GAF: M = 51.90 vs. 55.88; df = 111;
t = −3.51; p < 0.01), and diminishing in severity of illness
(BPRS: M = 21.23 vs. 17.81; df = 111; t = 4.0; p < 0.01).
However, during the follow-up period, extrapyramidal
side effects were increased (SAS: M = 0.14 vs. 0.21;
df = 99; t = −2.85; p < 0.01), and ratings of drug-
induced akathisia (BAS), and abnormal movements
(AIMS) did not change significantly. Correlations of
these variables with the SWN-K-E scores were assessed. A
modest positive relationship appeared between the SWN-
K-E total scores and the observer-rated global functioning
(GAF) scores (r = 0.21; p < 0.05). No relationships were
found between SWN-K-E and psychopathology (BPRS),
nor drug side effects (SAS, BAS, and AIMS) scores. These
results indicate that the subjective well-being index was
not contributed by the demographic variables, BMI, se-
verity of psychopathology, side-effects, and drug dosage,
but it was associated with independently rated global
functioning.
Discussion
With an increasing awareness of the variability of treat-
ment outcome and the importance of patient subjective
experiences under the treatment, the construct of well-
being has become an important area of investigation in
psychotic disorder research [38]. Self-report measure-
ments may provide the most direct access to theindividual's perceptions of interested domain and there-
fore, the SWN-K-E scale was adapted as an instrument
for research and clinical practice in order to assess the
subjective well-being in different dimensions of patients
with psychotic disorder treated with antipsychotics.
The process of the instrument development and ana-
lysis of validity and reliability results have been rigor-
ously described. Findings provide evidence for adequate
internal consistency, as well as for construct validity for
the adapted scale. The internal consistency for the
adapted scale was found to be the same level with the
original scale (Cronbach's α = 0.93) [23] and the subscale
reliabilities ranged from 0.70 to 0.87. It may therefore be
said that the Estonian version of the SWN-K scale is suffi-
ciently internally consistent. In addition, results of the
principal component analysis indicated that the SWN-K-E
demonstrates the five dimensional factor structure, similar
to original scale [23]. The component correlations ranged
from r = 0.24 to 0.36 suggesting a second-order factor
may underlie them. Based on the results, hierarchical con-
firmatory factor analysis was used to evaluate the structure
of the final version of the adapted scale. Five first-order
factors (MF, PF, SC, SI, ER) were specified, as per original
SWN-K scale [23], and a general higher-order factor. The
results of the analysis supported the existence of a higher-
order factor (general well-being) and clarified its asso-
ciations with the first-order factors. The evidence from
the current study suggest that, as an alternative factor ana-
lytic model, CFA may offer better understanding of the
SWN-K factor structure; in particular, it can be used to
estimate and parameterize the hierarchical structure of
the construct of well-being in psychotic disorder patients.
To evaluate the preliminary convergent validity of the
scale, patients were asked to rate how satisfied they
generally were with their lives. Moderate correlations
(r = 0.37 to 0.54) were found between this statement
and the SWN-K-E scores. In interpreting these results, it
should be considered that single item was used in the
comparison, which, due to relatively lower reliability
compared to multi-item measures, may have lead to an
underestimation of the effect size. In addition, our results
showed a weak correlation between SWN-K-E total score
and general functioning (GAF). This is in agreement with
previous studies [10]. The discriminant validity was exam-
ined by looking at the cross-construct correlations which
ranged from 0.05 (AIMS) to −0.11 (BPRS). Consistent
with previous studies, we found that the patients' subject-
ive well-being was not associated with symptom severity
[23] or medication side effects [10]. Our study could not
establish the criterion and concurrent validity by reason of
lacking of properly adapted existing instruments in the
area of health-related quality of life among the psychotic
patients in Estonia. There is a need for additional valid-
ation studies on the SWN-K-E scale.
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of the assessment of subjective well-being in the course
of antipsychotic treatment. The patient satisfaction with
antipsychotic therapy seems to correlate strongly to the
clinically important aspect of the illness management -
patient's adherence to treatment [39]. Moreover, the
impact of antipsychotic drugs on subjective well-being
has been a controversial issue [10,12]. We did not find a
significant association of changes in SWN-K-E total
scores and medication type or daily dose of antipsychotic
agents. The fact that no differences with regards to
SWN between people under different antipsychotic
treatment were detected in this sample should be inter-
preted with caution. Due to the small sample size in the
typical antipsychotic treatment subgroup, there was not
enough statistical power to exclude false-negative results.
Moreover, we did not implement controlled drug change
intervention and the patients were not taking only
antipsychotics during the study period. Stability of the
measurement versus sensitivity to change is an import-
ant issue for the adapted instrument. Therefore, whether
a high degree of stability is encouraging or discouraging
for the considered interpretation depends upon the
theory defining the construct [40]. Our study provided
evidence for the average stability of well-being judg-
ments (retest reliability).
It has been demonstrated that most psychiatric
patients are reliably and consistently able to express
their inner feelings and their level of satisfaction [41,42].
However, when employing self-evaluating scales in psy-
chiatric patient groups, we should acknowledge that the
lack of insight into their illness, affective and cognitive
symptoms or reality distortion may imply difficulties in
understanding the items of the scale [43], which may
impair scale validity.
The subjects included in this study were symptomatic
but stable psychotic patients, maintained on regular
antipsychotic therapy. Such a profile closely resembles
the type of patients seen in psychiatric clinics. Regard-
less, the serious mental illness the majority of participat-
ing patients seemed to be quite satisfied with their life.
Limitations
The results of this study should be interpreted with
caution because of several methodological limitations.
Firstly, this work was limited with respect to its sample,
foremost in terms of size. Our study provides preli-
minary findings; further research examining individuals
diagnosed with psychotic illness with varying clinical
presentations and under the different treatment settings
is warranted in order to delineate the potential pre-
dictors of well-being in this clinical group. Secondly, the
heterogeneity of our study sample may create important
generalizability problems. We cannot be sure to whatextent these findings can be extended to other specific
subgroups of psychotic patients, especially those with
severe cognitive impairment and judgement difficulties.
Thirdly, the extent of well-being and its determinants
need to be investigated more longitudinally, to study
subtle changes throughout the course of mental illness.
For further studies, focusing on different groups in
terms of age, more detailed social characteristics, and
how different cognitive dysfunction domains affect the
well-being judgements are recommended. Fourthly, fur-
ther research is needed to evaluate the criterion validity
of the SWN-K-E.
Nonetheless, this work provides support for the use of
SWN-K-E to measure the subjective well-being cons-
truct of the psychotic patients in research and clinical
purposes.
Conclusions
Taken together, we provided some evidence that adapted
SWB-K-E scale is a reliable and valid instrument for
measuring the subjective well-being among the patients
who are suffering from psychotic illness. Our study iden-
tified the theoretical structure of the adapted SWN-K
scale and suggests that the total score and subscores of
the scale could be used as indicators for the total or
specific domain of the construct.
Clinicians should become more aware of the subjec-
tively distressing nature of the psychotic illness as well
as the impact of the antipsychotic drug therapy on the
well-being, and take into consideration the patients'
evaluations while managing multidimensional approach
to the treatment. The assessment of well-being is not
redundant and information on their well-being may
further help to improve the quality of life care of people
with mental illness.
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